Exemplar Genetics

exemplargenetics.com

At Exemplar Genetics, we enable discovery by providing the vehicle to break new ground on the medical research frontier. Until now, researchers have lacked animal models that faithfully represent human diseases. As a result, a sizeable barrier has blocked progress in the discovery of human disease mechanisms; novel diagnostics, procedures, devices, prevention strategies and therapeutics; and the ability to predict in humans the efficacy of those next-generation procedures, devices, and therapeutics.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

PRELLIS BIOLOGICS ANNOUNCES COLLABORATION AND LICENSE AGREEMENT WITH BRISTOL MYERS SQUIBB

Prellis Biologics, Inc. | January 14, 2022

news image

Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system based on human lymph node organoids. The collaboration leverages Prellis’ EXIS platform that can break tolerance mechanisms in vitro to create high affinity human antibodies targeting human proteins. ...

Read More

Medical

GENOMIC VISION ENTERS DISTRIBUTION AGREEMENT WITH CLINISCIENCES

biotechnology news | June 23, 2023

news image

Genomic Vision a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, is pleased to announce an exclusive European distribution agreement with CliniSciences. CliniSciences is a major European distributor of innovative products and services in Life Science Research with a particular focus on oncology. CliniSciences and Genomic Vision will work closely together to leverage their respective resources, i...

Read More

SUTRO BIOPHARMA DEMONSTRATES STRO-002'S IMMUNE-MODULATING PROPERTIES AT AACR 2020

Sutro Biopharma | June 22, 2020

news image

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the presentation of new preclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate, STRO-002, at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020. The data,...

Read More

Industry Outlook

MUSTANG BIO ANNOUNCES STRATEGIC MANUFACTURING PARTNERSHIP AND PORTFOLIO UPDATES

Globenewswire | May 19, 2023

news image

Mustang Bio, Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced a strategic update, including anticipated milestones for 2023. Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology. Additionally, Mustang announced a partnership with uBriGene (...

Read More
news image

Research

PRELLIS BIOLOGICS ANNOUNCES COLLABORATION AND LICENSE AGREEMENT WITH BRISTOL MYERS SQUIBB

Prellis Biologics, Inc. | January 14, 2022

Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system based on human lymph node organoids. The collaboration leverages Prellis’ EXIS platform that can break tolerance mechanisms in vitro to create high affinity human antibodies targeting human proteins. ...

Read More
news image

Medical

GENOMIC VISION ENTERS DISTRIBUTION AGREEMENT WITH CLINISCIENCES

biotechnology news | June 23, 2023

Genomic Vision a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, is pleased to announce an exclusive European distribution agreement with CliniSciences. CliniSciences is a major European distributor of innovative products and services in Life Science Research with a particular focus on oncology. CliniSciences and Genomic Vision will work closely together to leverage their respective resources, i...

Read More
news image

SUTRO BIOPHARMA DEMONSTRATES STRO-002'S IMMUNE-MODULATING PROPERTIES AT AACR 2020

Sutro Biopharma | June 22, 2020

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the presentation of new preclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate, STRO-002, at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020. The data,...

Read More
news image

Industry Outlook

MUSTANG BIO ANNOUNCES STRATEGIC MANUFACTURING PARTNERSHIP AND PORTFOLIO UPDATES

Globenewswire | May 19, 2023

Mustang Bio, Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced a strategic update, including anticipated milestones for 2023. Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology. Additionally, Mustang announced a partnership with uBriGene (...

Read More